The letter came in June. Mindy McCormick, 67, read that her insurer would soon stop covering the weight loss drug Wegovy, which she had been taking for more than two years. What? she remembers thinking.

A new class of weight loss drugs developed by Novo Nordisk and Eli Lilly “opens the possibility of an end to the obesity pandemic” alongside other interventions, the World Health Organization (WHO) said this week.

Up to a third of the weight lost while taking weight loss jabs such as Wegovy and Mounjaro includes muscle and bone mass.

Quartz spoke with Noom CEO Geoff Cook to get his take on what 2025 holds for the compounded drug market and the overall future of weight-loss drugs. Cook took over as CEO of the psychology-based weight loss app Noom in 2023,

Powerful weight-loss drugs are expanding use of U.S. health care as patients starting prescriptions are diagnosed with obesity-related conditions or take the drugs to become eligible for other services,

People struggling with their body weight experienced joy when new, more effective prescription drug options became the rage in 2023, but it seems many folks stopped taking them in 2024.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for treating moderate to severe obstructive sleep apnea.

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and diabetes will need to phase out their versions next year under a federal decision issued Thursday.